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Abstract
The Tasmanian devil faces extinction due to devil facial tumour disease (DFTD), a highly transmittable clonal form of
cancer without available treatment. In this study, we report the cell-autonomous antiproliferative and cytotoxic
activities exhibited by the spider peptide gomesin (AgGom) and gomesin-like homologue (HiGom) in DFTD cells.
Mechanistically, both peptides caused a significant reduction at G0/G1 phase, in correlation with an augmented
expression of the cell cycle inhibitory proteins p53, p27, p21, necrosis, exacerbated generation of reactive oxygen
species and diminished mitochondrial membrane potential, all hallmarks of cellular stress. The screening of a novel
panel of AgGom-analogues revealed that, unlike changes in the hydrophobicity and electrostatic surface, the cytotoxic
potential of the gomesin analogues in DFTD cells lies on specific arginine substitutions in the eight and nine positions
and alanine replacement in three, five and 12 positions. In conclusion, the evidence supports gomesin as a potential
antiproliferative compound against DFTD disease.
Introduction
The Tasmanian devil (Sarcophilus harrisii) is the largest
extant carnivorous marsupial1. The Tasmanian devil is an
endangered Australian species, restricted to the island
state of Tasmania1, and threatened with extinction due to
a contagious and transmissible “parasitic” form of cancer
known as devil facial tumour disease (DFTD)2, which has
killed ~80% of the devil population since emerging in
19961. Primary tumours appear on the face or inside the
mouth and develop into large globular tumours that
metastasize in a short period of time to internal organs
and spread among individuals by biting during mating
and territorial fighting3. Ultimately, DFTD leads to death
within 3–6 months of the first appearance of clinical
symptoms4. Although the disease emerged ~20 years ago
in north eastern Tasmania, it now occupies most of the
devil’s distribution with only small portions of the west
and north western areas of the state remaining DFTD-
free1,4. Modelling studies have estimated that without
intervention the Tasmanian devil will extinct within the
next 15–25 years4.
With no treatment available for DFTD, scientists
maintain captive, disease-free breeding populations that
are released into the wild. Major research efforts are
focused on understanding the molecular mechanisms of
DFTD and why tumour cells fail to stimulate an immune
response in the Tasmanian Devil, including the dramatic
downregulation of the expression of Major Histo-
compatibility Complex (MHC) Class I genes5–9. Previous
trials to treat DFTD using human chemotherapeutic
agents, such as vincristine, doxorubicin, and carboplatin
have proven to be unsuccessful10,11. In this study, we
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postulated that spider peptides with vast pharmacology
and activities ranging from analgesic to antimicrobial and
antiproliferative properties12 may constitute a source of
therapeutic leads against DFTD.
In order to test our hypothesis, we examined, for the
first time in vitro, the anti-proliferative properties of the
spider-venom peptide gomesin and its analogues as
potential therapeutic lead candidates against DFTD.
AgGom is an 18-residue peptide with documented
anticancer activity13,14 that was first isolated from
hemocytes of the South American mygalomorph spider
Acanthoscurria gomesiana. Current studies from our lab
have shown that AgGom and a gomesin analogue
(HiGom) isolated from the Australian funnel-web spider
Hadronyche infensa have similar antiproliferative
properties (Ikonomopoulou et al., under review). This
observation prompted us to characterise the cell-
autonomous cytotoxic and anti-proliferative profile of
gomesin in DFTD cells and in comparison, to non-
transformed (healthy) Tasmanian devil fibroblasts (FIBS).
In addition, we designed and screened a panel of gomesin
analogues with amino acid modifications that were pre-
dicted to influence cell viability. Therefore, this study
provides fundamental mechanistic insights into the anti-
proliferative properties of gomesin in DFTD.
Results
Gomesin peptides compromise DFTD4 cell viability
We used DFTD4 cell line as a DFTD cellular model to
study the antiproliferative and apoptotic properties of
gomesin peptides. First, we examined the potential cyto-
toxic and anti-proliferative effects of gomesin peptides by
determining whether the viability of DFTD4 and FIBS
cells was altered by 48 h exposure to either AgGom or
HiGom. While at high concentrations (50 µg/mL) both
AgGom and HiGom dramatically reduced the cell viability
of DFTD4 cells, their deleterious effects on FIBS were not
statistically significant (Fig. 1a, b). Most importantly, at
lower concentrations, HiGom was more cytotoxic than
AgGom to DFTD4 cells and it had negligible effects on
FIBS ranging from 0.5 to 25 µg/mL (Fig. 1a, b). In addi-
tion, HiGom had an EC50 of 18.43 µg/mL while AgGom
had an EC50 of 25.25 µg/mL. Hence, we concluded that
HiGom is a better candidate for inhibiting progression of
DFTD.
AgGom and HiGom peptides reduce DFTD4 cells at G0/G1
phase, leading to cell death
Treatment of DFTD4 cells for 24 h with AgGom or
HiGom induced a reduction of the cells in G0/G1 phase
(Table 1). This correlated with elevated ratios of unpro-
grammed cell death (necrosis) of gomesin-treated DFTD4
cells in comparison to vehicle-treated cells (Fig. 2, P<
0.05). In addition, the early or late apoptotic cell ratio was
not altered by gomesin treatments, while camptothesin, a
well-known cell death promoter, was less potent than
Fig. 1 Gomesin compromises the viability of DFTD4 cells.
Concentration-response data showing the effect of (a) AgGom and (b)
HiGom on the viability of DFTD4 and FIBS cells treated with gomesin
peptides for 48 h. Data are mean ± SEM. Experiments were performed
in triplicate and are the result of three independent experiments. *P <
0.05, **P < 0.001, **P < 0.0001 (ANOVA: DFTD4 vs. FIBS) and #P < 0.05,
##P < 0.001, ###P < 0.0001 (t-test: DFTD4, 0 vs. 50 μg/mL)
Table 1 The effect of AgGom and HiGom on cell cycle
progression
G0/G1 S-phase G2/M
Untreated cells 56.57 ± 9.5 8.58 ± 0.7 18.4 ± 1.5
AgGom 39.9 ± 1.32* 11.47 ± 1.35 14.3 ± 0.9
HiGom 47.2 ± 0.66** 13.7 ± 1.9 13.3 ± 0.7
DFTD4 cells were treated with 50 μg/mL AgGom or HiGom for 24 h. Changes in
cell cycle (G0/G1, S and G2/M phases) were analysed using FlowJo v10.06. Data
are mean ± SEM and are the result of three independent experiments
*P < 0.05, **P < 0.001 (t-test or Wilcoxon test, relative to untreated cells).
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gomesin peptides (Fig. 2). To further comprehend the
molecular mechanism that resulted in impaired cell cycle
progression, cell viability, and stimulation of necrosis, we
examined the gene expression of major cell cycle check-
points (p19, p21, and p27) and proteins promoting cell
death (BIM, BAD, and p53) but also the pro-survival
proteins: BCL2 andMCL1. AgGom and HiGom enhanced
the expression of p53 and BCL2 (Fig. 3). Furthermore,
AgGom showed a specific cellular signature in compar-
ison to HiGom. Specifically, while p27 expression was
elevated by both gomesin peptides, a statistically sig-
nificant increase occurred only in AgGom-treated cells
(Fig. 3). Moreover, AgGom-treated cells were char-
acterised by induction of p21 and the pro-survival gene
MCL1 (Fig. 3).
HiGom and AgGom enhance ROS content and diminish
MMP in DFTD4 cells
Excessive accumulation of reactive oxygen species
(ROS), as well as loss-of-mitochondrial membrane
potential (MMP) are molecular hallmarks of cancer cells.
While normally p53 induces cell cycle arrest followed by
apoptosis, as an exceptional situation, in mouse and
human tumour cells enhanced activity of p53 has been
linked to cell necrosis and elevated ROS15. Accordingly,
elevated expression of p53 in response to gomesin treat-
ments was accompanied by cellular stress. DFTD4 cells
exposed to AgGom or HiGom for 24 h, exhibited a sig-
nificant increase in ROS similar to those cells treated with
our positive control of cellular stress, camptothecin16
(Fig. 4a). Moreover, AgGom and in a more profound
manner HiGom (50 µg/mL, 24 h), caused a significant
decrease in MMP in DFTD4 cells (Fig. 4b) in comparison
to cells exposed to vehicle and to the positive control
carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
(HiGom vs CCP; ANOVA, F4,5= 15, p= 0.0038)
16
(Fig. 4b).
Branched and positively charged amino acids mediate
gomesin cytotoxicity
The results presented in the previous sections from
functional and biochemical comparisons between
HiGom (ZCRRLCYRNRCVTYCRGR) and AgGom
(ZCRRLCYKQRCVTYCRGR) implied that subtle mod-
ifications in the amino acid sequence (KQ8, 9RN,
Table 2) constitute a feasible strategy to improve the
anti-proliferative properties of gomesin against DFTD
cells. Therefore, we designed a panel of analogues using
single-amino acid substitutions of the two-residue motif
that differentiates AgGom from HiGom (KQ vs. RN,
Table 2). In addition to HiGom mutant, we synthesised
AgGomRQ (K8R), AgGomKR (Q9R) and AgGomKN
(Q9N). Moreover, based on alanine substitutions known
to affect hydrophobicity and electrostatic surface
potential of the peptide, we synthesised AgGomR3A,
(R3A) AgGomL5A (L5A) and AgGomV12A (V12A).
Finally, using the methodology previously described for
the characterisation of HiGom (Ikonomopoulou et al.,
under review), we generated and tested a gomesin ana-
logue isolated from the Selenotypus plumpis (SpGom;
ZCRRICGRRRCFTYCRGR), whose sequence differs
from AgGom by five residues (L5I, Y7G, K8R, Q9R, and
V12F). In order to confirm the cytotoxic profile of
gomesin and analogues, we tested them in DFTD4 and
in two additional DFTD cell lines (i.e., DFTD1 and
DFTD2). We observed that AgGomKN, AgGomKR, as
well as SpGom exhibited higher anti-proliferative
activity than AgGom and had minimal deleterious
effects on FIBS cells (Fig. 5a–c). In addition, by exam-
ining the gomesin analogues, SpGom, AgGomKR, and
HiGom, we observed that from each of the two amino
acids that distinguished HiGom from AgGom, sub-
stitution of K or Q in positions 8 and 9 by arginine (R)
are the more critical amino acid modifications driving
and promoting the anti-proliferative properties of
gomesin (Fig. 5a–c) (Table 2). Conversely, alanine sub-
stitutions in residues 3, 5, and 12 (AgGomR3A,
AgGomL5A and AgGomV12A, respectively) eradicated
the anti-proliferative activity of AgGom (Fig. 5c).
Therefore, our mechanistic experimental approaches
have identified key residues in AgGom that mediate its
anti-proliferative and cytotoxic properties in DFTD
cells.
We postulated that changes in the anti-proliferative
properties of the different gomesin peptides might be a
consequence of structural changes in the peptides or dif-
ferences in conformational flexibility. At the conformational
level previous studies using NMR revealed that AgGom
adopts a two-stranded antiparallel β-sheet structure that is
Fig. 2 AgGom and HiGom induce necrosis of DFTD4 cells. AgGom
and HiGom significantly increased necrosis of DFTD cells compared to
untreated cells. Cells treated with camptothecin (Campto, 10 µM, 24 h)
were used as a positive control (>30% late apoptosis). Data are mean
± SEM from three independent experiments. Statistics are relative to
untreated cells and are represented as: *P < 0.05, **P < 0.001 (t-test or
Wilcoxon test)
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stabilised by two intra-strand disulfide bonds17. However,
our analysis of 3000 structures from the combined trajec-
tories clustered using a cutoff of 0.30 nm, an overlay of 20
conformations selected at random from the combined tra-
jectory (Fig. 6a), as well as a root-mean square fluctuation
analysis (RMSF) (data not shown), suggest that the level of
conformational flexibility of AgGom is higher than expec-
ted from its NMR structure. As a result of this flexibility, the
AgGom peptide can adopt a range of conformations in
which the two strands are in different relative orientations
(Fig. 6a). Despite these motions, the backbone–backbone
hydrogen bonds characteristic of the β-sheet structure of
AgGom are present for most of the simulation with dis-
tances between 0.16 and 0.25 nm. Only the hydrogen bond
between pE1 and R3 is transient due to the flexibility of the
C-terminus (Fig. 6a).
Comparative MD simulations of HiGom, AgGomKR,
SpGom, AgGomL5A, AgGomR3A, and AgGomV12A
with AgGom determined that amino acid substitutions in
gomesin analogues do not confer structural modifications
and different conformational dynamics that could explain
their different cytotoxicity to DFTD cells (Fig. 6b).
Comparison of the different structures shows that the C-
terminus and the β-hairpin loop are the most flexible
parts of the peptide and exhibit the same twisting and
bending motions of the β-strands as seen in the AgGom
simulations (Fig. 6b). RMSF analysis showed that SpGom,
which exhibits a higher antiproliferative activity than
AgGom and AgGomL5A, which lacks cytotoxicity prop-
erties, are more flexible than AgGom (Fig. 6b) while
AgGomR3A is the least flexible and all other gomesin
variants show RMSF profiles similar to AgGom.
Fig. 3 AgGom and HiGom stimulate the expression of cell cycle check-point, pro-survival and apoptosis-related genes in DFTD4 cells.
Expression of cell cycle check-point genes (p16, p21, p27, and p53) and pro-survival/apoptosis-related (BCL2, MCL1, BAD, and BIM) genes in DFTD4
cells treated with 50 μg/mL AgGom (red bars) or HiGom (green bars) DFTD4. Gomesin-treated cells were compared to vehicle-treated cells (white
bars) and are shown as mean ± SEM of three independent experiments. *P < 0.05 (t-test: AgGom or HiGom vs. vehicle)
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Therefore, changes in the conformational flexibility of the
gomesin analogues do not either underlie their distinct
anti-proliferative properties in DFTD cells.
Single-amino acid substitutions might also change the
electrostatic potential surface of the peptide (Fig. 6c),
which could affect their activity on DFTD cells, for
example by altering the interaction of the peptide with the
head groups of lipid molecules at the plasma membrane.
Comparison of the different peptide variants shows that,
as expected, substitutions of charged residues in
AgGomKR, SpGom, and AgGomR3A have the largest
effect on the electrostatic potential surface. Replacement
of Q9 and/or K8 residues by arginine in AgGomKR and
SpGom, respectively, increased the positive charge in the
β-hairpin turn, resulting in a larger positively charged
surface compared to AgGom. Conversely, substitutions
outside the turn region, such as replacing R3 with alanine
reduces the positive charge making the peptide surface
more neutral compared to AgGom (Fig. 6c). However,
amino acid substitutions in HiGom (K8R, Q9N) have no
notable impact on the electrostatic potential surface
despite increasing the cytotoxic activity of the peptide
(Fig. 6c). Reduced electrostatic potential surface was also
observed with either L5A or V12A substitutions in
AgGomL5A and AgGomV12A, respectively (Fig. 6c).
Nonetheless, and although not visible on the electrostatic
potential surface, replacing L5 and V12 will reduce the
hydrophobicity of the peptide, a property that is not
observed in AgGomR3A, the other AgGom analogue
lacking cytotoxic activity in DFTD cells. Moreover, when
trying to explain the lack-of cytotoxic activity in
AgGomR3A, AgGomL5A and AgGomV12A, we observed
that L (leucine) and V (valine) are both branched and
hydrophobic amino acids while R (arginine) is a positively
charged amino acid. Therefore, changes in the electro-
static potential surface and type of amino acids do not
either explain the cytotoxic activities of the different
AgGom analogues Table 3.
Discussion
Gomesin kills DFTD cells by necrosis
In this pioneer study, we examined for the first time, in
our knowledge, the therapeutic potential of spider-venom
peptides against DFTD. Our study provides a molecular
and mechanistic characterisation of the mode of action of
gomesin peptides to prevent the proliferation of DFTD
cells. This is especially relevant since the Tasmanian devil
population has declined by at least 80%1 and currently the
therapeutic strategies to slow down the progression of
Fig. 4 AgGom and HiGom increase ROS generation and reduce
MMP in DFTD4 cells. a AgGom and HiGom (50 μg/mL, 24 h)
increased ROS production in DFTD4 cells. Camptothecin (Campto, 10
µM, 24 h) was used as a positive control. b MMP in DFTD4 was
significantly reduced after treatment with AgGom or HiGom. CCCP
(0.5 mM, 12 h) was used as a positive control for MMP reduction. Data
are mean ± SEM and are the result of three independent experiments.
Statistics is relative to untreated cells and are represented as: *P < 0.05,
**P < 0.001 (t-test or Wilcoxon test)
Table 2 Amino acid sequences of AgGom, HiGom, and
seven analogues
Analogue Sequence
AgGomRQ ZCRRLCYRQRCVTYCRGR-NH2
AgGomKN ZCRRLCYKNRCVTYCRGR-NH2
SpGom ZCRRICGRRRCFTYCRGR-NH2
AgGomKR ZCRRLCYKRRCVTYCRGR-NH2
AgGom ZCRRLCYKQRCVTYCRGR-NH2
HiGom ZCRRLCYRNRCVTYCRGR-NH2
AgGomR3A ZCARLCYKQRCVTYCRGR-NH2
AgGomL5A ZCRRACYKQRCVTYCRGR-NH2
AgGomV12A ZCRRLCYKQRCATYCRGR-NH2
In bold are the substituted from AgGom amino acids.
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DFTD in infective-devils have been ineffective. That was
the case of vincristine, a chemotherapeutic agent used in
human and veterinary medicine,10 as well as carboplatin
and doxorubicin11. Only the immunomodulatory mole-
cule imiquimod displayed apoptotic activity against cul-
tured DFTD cells7. Therefore, novel compounds targeting
DFTD cells are urgently needed. Regarding this, we
believe that our data provide persuasive evidence of the
specific-cytotoxic potential of gomesin peptides against
DFTD cells. Indeed, ongoing studies in our lab corrobo-
rated and validated the cytotoxic properties exhibited by
AgGom and HiGom on tumour cells (MM96L melanoma
cells) in comparison to non-transform fibroblasts (Iko-
nomopoulou et al., under review). Moreover, and in
agreement with the results obtained in melanoma
MM96L cells (Ikonomopoulou et al., under review),
HiGom seems to be a better therapeutic lead since it
exhibited more dramatic antiproliferative and cytotoxic
activity than AgGom in DFTD cells.
Mechanism of gomesin-induced death in DFTD cells
The mode of action of AgGom and HiGom in DFTD
cells shares molecular signatures with those observed in
gomesin-treated human MM96L melanoma cells,
including an increase of ROS and a reduction of MMP,
hallmarks of cell necrosis and apoptosis in drug-induced
cytotoxicity18,19. However, it is intriguing that unlike in
gomesin-treated melanoma cells that suffer cell apoptosis
(Ikonomopoulou et al., under review), gomesin-treatment
leads to necrosis in DFTD cells. It is unclear whether both
ROS generation and reduced MMP are causative factors
of gomesin-induced necrosis or a consequence of gomesin
cytotoxicity. However, and accordingly with the lack-of
apoptosis, the expression of pro-apoptotic genes, such as
BIM and BAD, both significantly upregulated in DFTD
cells when exposed to imiquimod for 72 h7, is unchanged
in gomesin-treated DFTD cells. Accordingly, gomesin
induced a reduction of the cell population present in G0/
G1 phase and elevated the expression of p53 and Bcl-2.
Fig. 5 Analysis of the cytotoxic activity of novel gomesin analogues in DFTD cell lines. a Concentration-response in DFTD1, DFTD2, and DFTD4
cells exposed to 6.25, 12.50, 25, and 50 μg/mL of the analogues AgGomRQ, SpGom, AgGomKN, and AgGomKR for 48 h in comparison to AgGom and
HiGom (b) FIBS and (c) DFTD4 cells treated for 48 h with 50 μg/mL of the analogues AgGomRQ, SpGom, AgGomKN, AgGomKR, AgGomL5A,
AgGomV12A, and AgGomR3A in comparison to AgGom and HiGom. Data are shown as mean ± SEM and are the result of three independent
experiments. Two Way-ANOVA was used to evaluate statistical difference between AgGom and the analogues, as well as ANOVA to determine
differences between untreated cells and analogues (FIBS) and AgGom and analogues (DFTD4). ***P < 0.001, ****P < 0.0001
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While excessive and chronic increased expression of p53
may lead to apoptosis, p53, like Bcl-2, is originally con-
sidered as a pro-survival protein in response to deleter-
ious environmental and cellular stress that cause cell cycle
arrest and senescence20. In gomesin-treated DFTD cells,
and although statistically significant, the stimulation of
p53 and Bcl-2 expression is not higher than 1.5-fold the
level observed in vehicle-treated DFTD cells, suggesting
that in this case p53 and Bcl-2 may contribute to a pro-
survival signalling to maintain cell integrity rather than
causing apoptosis. Hence, our study suggests that gome-
sin exhibits a DFTD cell-specific and autonomous mode
of action. Interestingly, AgGom and HiGom cytotoxic
profiles demonstrated certain molecular differences.
While it is possible that by stimulation and functional
coordination of p53 and p27 both peptides regulate cell
Fig. 6 Representation of the structural conformation, hydrophobicity and electrostatic potential surface of native gomesin and analogues.
a Structure of AgGom, including from left to right: NMR structure of native AgGom (PDB id 1KFP); representative structure of the predominant
conformation of AgGom identified by clustering analysis of 3000 structures; overlay of 20 conformations from MD simulations of AgGom (the NMR
structure is shown in dark blue as a reference). Structures are coloured according to secondary structure with β-strands in orange, turns in cyan and
unstructured coils in white. Disulfide bonds are shown in yellow. b Structure of Gomesin variants from MD simulations. For each variant the structure
shown is the predominant conformation identified by clustering analysis of 1200 structures. Structures are coloured according to secondary structure
with β-strands in orange, turns in cyan, and unstructured coils in white. Disulfide bonds are shown in yellow. For variants, the side-chain of mutated
residues is shown. c Electrostatic potential surfaces of native AgGom and gomesin variants. Structures are coloured from most electronegative (red)
to most electropositive (blue)
Table 3 The EC50 values of AgGom, HiGom, and the cytotoxic gomesin analogues in three different DFTD cell lines
EC50 (µg/mL) AgGomRQ AgGomKN SpGom AgGomKR AgGom HiGom
DFTD1 14.54 11.5 12,5 8.4 20.4 14.96
DFTD2 13.87 10.62 4.95 12.47 12.29 13.06
DFTD4 23.08 27.4 18.35 16.76 20.41 14.96
The EC50s highlighted in bold are the best concentration values of the gomesin analogues observed in each DFTD cell line in comparison to AgGom and HiGom.
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growth arrest, AgGom-treated DFTD cells reveal a unique
signature involving upregulation of p21, another canoni-
cal cellular cell cycle check-point, and the anti-apoptotic
gene MCL1. Hence, the data presented in this study
suggest that there are mechanistic differences among
gomesin peptides.
Characterisation of critical amino acid residues for gomesin-
cytotoxic properties
The significance of this study is also underscored by the
delineation of key residues responsible of gomesin cyto-
toxicity in DFTD cells, essential to further our under-
standing of the molecular mechanism of action of
gomesin and the application of medicinal chemistry to
design novel gomesin-based therapeutic strategies against
DFTD. Critically, MD simulations and NMR determina-
tions showed that the gain-of or lack-of anti-proliferative
activities exhibited by the gomesin analogues were not
mediated by changes in the peptide flexibility and/or
conformations but as an intrinsic property of the different
amino acid substitutions. It is feasible that like in other
anti-proliferative or cell-penetrating peptides21,22, gome-
sin cytotoxic properties are governed by its interactions
with the cell membrane. In linear homologues of gomesin
it has been shown that membrane permeabilizing capacity
is linked to the β-sheet motif23–25 and to hydrophobic
residues, such as L5, Y7, and V12, which substitution
results in reduced binding affinity to phospholipids and
the ability to permeabilize membranes26. Our experiments
using gomesin analogues showing substitutions of L5 and
V12 by alanine are consistent with these studies. How-
ever, lack-of cytotoxic properties in the variant
AgGomR3A despite its predicted increased binding to
phospholipid vesicles and higher leakage than AgGom26
suggest that might exist other mechanisms mediating the
deleterious effects on DFTD cells. Our studies of gomesin
variants also confirm the important role of charged resi-
dues in the turn region. Indeed, these electrostatic inter-
actions are believed to be an important factor in the
selective cytotoxicity of anticancer peptides, such as
AgGom21,22. In the SpGom and AgGomGR variants, that
exhibit increased cytotoxicity in all three tested DFTD
strain cell lines but minimal effects on FIBS, the positive
electrostatic potential surface is larger than in AgGom
and extends to the β-turn. We hypothesise that this may
be related to the fact that an increased positive surface will
enhance gomesin preference for negatively charged
membranes24, which is the case of cancer cell membranes
due to their high content in anionic lipids26.
In summary, taken together, the mechanistic char-
acterisation of gomesin cytotoxic properties, as well as the
design of powerful analogues and computational simula-
tion approaches represent a significant step forward in
understanding the molecular mechanism of gomesin-like
peptides in order to apply medicinal chemistry and design
gomesin-based therapeutic strategies against DFTD.
Materials and methods
All reagents were obtained commercially and were used
without further purification. Fmoc–protected L-amino acids
Arg(Pbf), Asn(Trt), Cys(Trt), Gln(Trt), Gly, Leu, Lys(Boc),
Phe, Thr(tBu), Tyr(tBu), and Val were purchased from IRIS
Biotech (Marktredwitz, Germany), Bachem (Bubendorf,
Switzerland), or ChemImpex (Wood Dale IL, USA).
Unprotected L-pyroglutamic acid, dimethylsulfoxide
(DMSO), triisopropylsilane (TIPS), diethyl ether, iodine,
ascorbic acid and ammonium bicarbonate were purchased
from Sigma-Aldrich (Castle Hill, Australia). Rink Amide
polystyrene resin and N,N-diisopropylethylamine (DIEA)
were purchased from Auspep (Tullamarine, Australia).
Coupling reagent O-(6-Chlorobenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluoro-phosphate (HCTU) was
purchased from ChemImpex (Wood Dale IL, USA), while
N,N-dimethylformamide (DMF) and HPLC-grade acetoni-
trile were obtained from RCI Labscan (Bangkok, Thailand)
and trifluoroacetic acid (TFA) and piperidine were purchase
from Chem-Supply (Gillman, Australia).
Bacterial culture media from Bacto Laboratories (Mt
Pritchard, Australia), and enzymes from Invitrogen and
Life Technologies (Sydney, Australia). RPMI-1640 and
AmnioMAX-C100 Basal Medium liquid and supplement
were obtained from Invitrogen (Sydney, Australia).
Annexin V-FITC Apoptosis detection kit was from BD
Biosciences (San Diego, USA). Carboxy-H2DCFDA was
from Invitrogen (Carlsbad, Australia). Rhodamine123,
Propidium iodide (PI) and MTT kits were purchased from
Sigma-Aldrich (Sydney, Australia), while primers were
from Integrated DNA Technologies (Singapore Science
Park II, Singapore).
Selection of gomesin sequences for synthesis
AgGom and HiGom were synthesised as described
below. We also synthesised peptides with modifications in
the residues that differ between AgGom and HiGom and
investigated whether these analogues would improve their
anti-proliferative properties (Table 2, peptides
AgGomRQ, AgGomKN, SpGom, and AgGomKR). We
also substituted specific residues with alanine, following
literature reports26, suggesting that these mutations alter
binding affinity to lipids and lytic activity in AgGom
(Table 2, AgGomL5A, AgGomV12A, and AgGomR3A).
Chemical synthesis of gomesin peptides
The nine peptides were assembled on a 0.1-mmol scale
using a Symphony automated peptide synthesizer (Protein
Technologies, Tucson, USA) and a Rink amide poly-
styrene resin (loading 0.79 mmol/g) following the Fmoc/
tBu-solid phase peptide synthesis (SPPS) protocol. Chain
Fernandez-Rojo et al. Cell Death Discovery  (2018) 4:19 Page 8 of 11
Official journal of the Cell Death Differentiation Association
assembly was performed in dimethylformamide (DMF)
using 5-equivalents of Fmoc amino acid (AA)/O-(6-
chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HCTU) and DIPEA (AA/HCTU/
DIPEA= 1:1:1) relative to resin loading for 2× 30min.
Fmoc deprotection was achieved using 30% piperidine/
DMF (1× 1.5 min, then 1× 4min). Fmoc amino acids
were side-chain protected as Arg(Pbf), Asn(Trt), Cys(Trt),
Gln(Trt), Gly, Leu, Lys(Boc), Phe, Pyr, Thr(tBu), Tyr(tBu),
and Val. Final cleavage and side-chain deprotection was
accomplished using 90% TFA, 5% TIPS, and 5% H2O for
90min at room temperature. The suspension was filtered,
washed with TFA and the filtrate concentrated under
steady N2 flow to a minimal amount. Subsequently, the
peptide was precipitated and washed with cold Et2O. The
precipitate was filtered off and then dissolved in 0.05%
TFA in 50% MeCN/H2O and lyophilised. The reduced
peptide was isolated by preparative reverse-phase (RP)
HPLC and pure fractions were combined and lyophilised.
Disulfide bond formation
Formation of the disulfide bonds was performed at
room temperature in 0.1M NH4HCO3 solution contain-
ing 10% DMSO (1mg peptide/ml) at pH 8.3 for 18 h.
Formation of the desired isoform was confirmed for all
synthetic peptides using a combination of RP-HPLC and
matrix-assisted laser desorption/ionisation mass spectro-
metry (MALDI-MS).
Molecular modelling of gomesin peptides
Unrestrained molecular dynamics (MD) simulations of
AgGom (native gomesin) and six variants
Details of the system setup and simulation parameters
can be found in the supplementary material. Briefly, the
NMR structure of gomesin (PDB-ID 1KFP17) was used as
a starting structure. The peptide was modelled with a L-
pyroglutamic acid (PCA) at the N-terminus and an ami-
dated arginine (ART) at the C-terminus, and native dis-
ulfide bonds Cys2–Cys15 and Cys6–Cys11. For the six
variants (HiGom, AgGomKR, SpGom, AgGomL5A,
AgGomR3A, AgGomV12A), amino acid substitutions
were introduced as outlined in Table 2. The peptide was
solvated with water molecules and the charge was neu-
tralised by adding Na+ ions. Further Na+ and Cl− ions
were added to represent a final, physiological ionic
strength of ~150mM NaCl. AgGom was simulated for
500 ns in triplicate and the six peptide variants were each
simulated for 300 ns in duplicate. All simulations were
carried out using GROMACS 4.6.727, in conjunction with
the GROMOS 54A7 forcefield28. The temperature and
pressure of the simulations system were maintained at
278 K and 1 bar for consistency with experimental con-
ditions under which the NMR structure of gomesin
(AgGom) was determined.
Simulations of a given peptide variant were combined
for analysis into a single-data set containing 3000 struc-
tures for AgGom and 1200 structures for each variant.
Conformational clustering, root-mean square deviation
(RMSD) and root-mean square fluctuation (RMSF) cal-
culations were carried out using GROMACS tools (Sup-
plementary Table 1). Electrostatic potential surfaces were
computed by solving the linearised Poisson–Boltzmann
equation using APBS software (www.poissonboltzmann.
org)29. All images were produced using VMD30. Details of
the analysis can be found in the supplementary material.
Cell lines
All DFTD (DFTD1, DFTD2, and DFTD4) and fibroblast
(FIBS) cell lines were obtained from the Department of
Primary Industries, Parks, Water, and Environment, State
Government of Tasmania (DPIPWE) and were estab-
lished as part of management plan and adhere to a stan-
dard operating practice. The DFTD1 cell line with
catalogue number 3287 is derived from the tumour from a
female devil (tag number: 06/2887) collected at St Marys,
Eastern Tasmania in 2006. DFTD2 cell line with catalogue
number 8961 was developed from a tumour from a male
devil (tag number: 12/0625) collected at Kempton,
Northern Tasmania in 2012. The DFTD4 cell line with
catalogue number 4099 was developed from the tumour
of a male devil (tag number: 07/0192) that was collected at
Freycinet, east coast of Tasmania in 2007 and Fibroblasts
cells (FIBS) with catalogue number 497 were obtained
from a healthy devil male pup (tag number: 05/0962) held
at Mount Pleasant, Southeastern of Tasmania in 2005.
Cell culture
Devil Facial Tumor cancer cell lines, and the control
Tasmanian Devil fibroblast (FIBS) healthy cell line were
maintained in a humidified incubator at 35 °C and 5%
CO2. The DFTD cell lines were cultured in RPMI-1640
medium supplemented with 10% FCS, and 2mM Gluta-
max. The FIBS was grown in GIBCO AmnioMAX-C100
Basal Medium liquid, containing AmnioMAX-C100 sup-
plement. Penicillin/streptomycin (PS) (100 U/ml each)
was added to both media. The cells were passaged at
~90% confluency. Functional studies were performed with
passages up to 20. All cell lines were mycoplasma free.
Cell viability
Cell viability as an indicator of the number of viable and
proliferative cells was measured by MTT according to the
protocol of the manufacturer (Sigma-Aldrich, Australia). In
brief, 8000 DFTD and 5000 FIBS cells/well were seeded in a
96-flat adherent microtiter well plate for 24 h to allow cell
adhesion. Gomesin peptides and/or analogues were then
added to the plates to measure MTT reduction. Plates were
measured after 48 h at 540 nm absorbance in a microplate
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reader (BIOTEK PowerWave XS, USA). 0.1% SDS was used
as a positive control (100% toxicity). A row of untreated
cells was used to define 100% viability and blank wells
containing only media were used to extract background.
The concentration of gomesin peptides causing 50% inhi-
bition (EC50) in DFTD and FIBS cells was determined using
GraphPad Prism Software (Graphpad Inc, USA).
Cell cycle
DFTD4 cells were synchronised by removing serum
from the medium for ~24 h. Cells were then transferred
into medium containing serum and treated with AgGom
or HiGom at 50 µg/mL for 24 h. Cells were detached
mechanically, washed with PBS and fixed with 70%
ethanol for ~1 h at 4 °C. Ethanol was removed by cen-
trifugation (453 g for 5 min) and cells were washed with
PBS. Cells were treated with 5 µL of 10 µg/mL ribonu-
clease A to remove RNA contamination and further
incubated for 1 h at 37 °C to allow release of low-
molecular weight DNA. Cell pellets were stained with
10 µL of propidium iodide (PI) (1 mg/ml) and analysed at
a maximum emission of 605 nm using a LSR Fortessa 5
analyser (BD Biosciences, San Diego, CA, US). Approxi-
mately 10,000 events were recorded and data were ana-
lysed using FlowJo software v10.06 (FlowJo, US).
Cell apoptosis
Apoptosis in DFTD4 cells treated with AgGom or
HiGom was measured using an Annexin V-FITC Apop-
tosis detection kit in combination with a Canto II high-
throughput fluorescence-activated cell sorter (BD Bios-
ciences, USA). Briefly, cells were seeded at a density of
100,000 cells/well in a round-bottom 96-well plate and
treated with 50 µg/mL AgGom or HiGom for 24 h. The
cells were collected mechanically, washed twice with PBS
and once with wash buffer provided by the manufacturer.
Cells were stained simultaneously with FITC-labelled
annexin V and PI for 30min in the dark and at room
temperature before being analysed.
Quantitative real time-PCR
Total RNA was extracted from both untreated (control)
and gomesin-treated DFTD4 cells using an RNeasy kit
(Qiagen, Australia) and 1 µg was reverse-transcribed into
cDNA using SensiFast (Bioline, UK). Quantitative real
time-PCR (qRT-PCR) to quantitate mRNA expression
was performed on a LightCycler Instrument (Roche
Molecular Biochemicals, Australia) with Tasmanian devil
18S used as the reference (housekeeper) gene. All primers
are listed in Supplementary. Table 2.
Reactive oxygen species
An Amplex Red Hydrogen Peroxidase assay kit (Invi-
trogen, Australia) was used to measure reactive oxygen
species (ROS) generation in DFTD4 cells. A fluorescence
probe that detects intracellular H2O2, Carboxy-
H2DCFDA, was added 30min prior to collecting cells to
measure ROS production in DFTD4 cells that were pre-
viously treated with gomesin peptides at 50 µg/mL for 24
h. Fluorescent cells were washed twice with PBS prior to
analysis on a FACSCalibur flow cytometer (BD Bios-
ciences, USA) using excitation and emission wavelengths
of 492 nm and 517 nm, respectively. Approximately
10,000 events were recorded per sample and the readout
was analysed using FlowJo software v10.06 (FlowJo,
USA).
Mitochondrial membrane potential
We measured the mitochondrial membrane potential
(MMP) using Rhodamine 123 (Rhod-123) (Sigma-
Aldrich, Australia), a cationic dye that is localised in
mitochondria. Loss-of-MMP results in loss-of-Rhod-123
fluorescence. Approximately 1× 106 DFTD4 cells treated
with AgGom or HiGom at 50 µg/mL for 24 h were col-
lected and resuspended in 0.1 ml of culture medium,
stained with 10 µg/mL Rhod-123 for 30 min, and then
washed with PBS. The intracellular concentration of
Rho123 was determined immediately after by flow cyto-
metry (BD Biosciences, USA) using an excitation wave-
length of 488 nm. The data were analysed using FlowJo
v10.06 (FlowJo, USA).
Statistical analysis
All data are expressed as mean± standard error of mean
(SEM) of three independent experiments. Statistical ana-
lyses employed Student’s t-test or ANOVA for compar-
ison between groups and control. P< 0.05 was considered
statistically significant. A non-parametric Mann–Whitney
test was used when populations within groups were not
normally distributed. Calculations were performed with
GraphPad Software (Graphpad Inc, USA).
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